References
- Loma I, Heyman R. Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol. 2011;9:409–416.
- Browne P, Chandraratna D, Angood C, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014;983:1022–1024.
- Singhal BS, Advani H. Multiple sclerosis in India: an overview. Ann Indian Acad Neurol. 2015;18:S2–S5.
- Lublin FD. New multiple sclerosis phenotypic classification. Eur Neurol. 2014;72:1–5.
- O’Gorman C, Lucas R, Taylor B. Environmental risk factors for multiple sclerosis: a review with a focus on molecular mechanisms. IJMS. 2012;13:11718–11752.
- Kakalacheva K, Münz C, Lünemann JD. Viral triggers of multiple sclerosis. Biochimica Et Biophysica Acta (BBA), Molecular Basis of Disease. 2011;1812:132–140.
- Ebers GC, Bulman DE, Sadovnick AD, et al. A population-based study of multiple sclerosis in twins. N Engl J Med. 1986;315:1638–1642.
- Nielsen NM, Westergaard T, Rostgaard K, et al. Familial risk of multiple sclerosis: a nationwide cohort study. Am J Epidemiol. 2005;162:774–778.
- Retterer K, Juusola J, Cho MT, et al. Clinical application of whole-exome sequencing across clinical indications. Genet Med. 2016;18:696–704.
- Xue Y, Ankala A, Wilcox WR, et al. Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome/genome sequencing. Genet Med. 2015;17:444–451.
- Pergam SA, Limaye AP; AST Infectious Diseases Community of Practice. Varicella Zoster Virus (VZV) in solid organ transplantation. Am J Transplant. 2009;9:S108–S115.
- Gilden DH, Vafai A, Shtram Y, et al. Varicella-zoster virus DNA in human sensory ganglia. Nature. 1983;306:478–480.
- Eshleman E, Shahzad EA, Cohrs RJ. Varicella zoster virus latency. Future Virol. 2011;6:341–355.
- Ann MA. Humoral and cellular immunity to varicella-zoster virus: an overview. J Infect Dis. 2008;197:S58–S60.
- Abendroth A, Kinchington PR, Slobedman B. Varicella zoster virus immune evasion strategies. Curr Top Microbiol Immunol. 2010;342:155–171.
- Najafi S, Ghane M, Yousefzadeh-Chabok S, et al. The high prevalence of the varicella zoster virus in patients with relapsing-remitting multiple sclerosis: a case-control study in the North of Iran. Jundishapur J Microbiol. 2016;9:e34158.
- Sotelo J, Ordoñez G, Pineda B, et al. The participation of varicella zoster virus in relapses of multiple sclerosis. Clin Neurol Neurosurg. 2014;119:44–48.
- Sotelo J, Corona T. Varicella zoster virus and relapsing remitting multiple sclerosis. Multiple Scler Int. 2011;2011:1.
- Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol. 2002;2:85–95.
- Jean-Philippe J, Paz S, Caputi M. hnRNP A1: the Swiss army knife of gene expression. Int J Mol Sci. 2013;14:18999–19024.
- Olson JK, Santos RA, Grose C. Varicella-zoster virus glycoprotein gE: endocytosis and trafficking of the Fc receptor. J Infect Dis. 1998;178:S2–S6.
- Lee S, Levin M. Novel somatic single nucleotide variants within the RNA binding protein hnRNP A1 in multiple sclerosis patients. F1000Res. 2014;3:132.
- Cansizoglu AE, Chook YM. Conformational heterogeneity of karyopherin beta2 is segmental. Structure. 2007;15:1431–1441.
- Fridell RA1, Truant R, Thorne L, et al. Nuclear import of hnRNP A1 is mediated by a novel cellular cofactor related to karyopherin-beta. J Cell Sci. 1997;110:1325–1331.
- Imasaki T, Shimizu T, Hashimoto H, et al. Structural basis for substrate recognition and dissociation by human transportin 1. Mol Cell. 2007; 28:57–67.
- Douglas JN, Gardner LA, Salapa HE, et al. Antibodies to the RNA-binding protein hnRNP A1 contribute to neurodegeneration in a model of central nervous system autoimmune inflammatory disease. J Neuroinflammation. 2016;13:178.
- Romano M, Buratti E, Romano G, et al. Evolutionarily conserved heterogeneous nuclear ribonucleoprotein (hnRNP) A/B proteins functionally interact with human and drosophila TAR DNA-binding protein 43 (TDP-43). J Biol Chem. 2014;289:7121–7130.
- Douglas JN, Gardner LA, Salapa HE, et al. Antibodies to the RNA binding protein heterogeneous nuclear ribonucleoprotein A1 colocalize to stress granules resulting in altered RNA and protein levels in a model of neurodegeneration in multiple sclerosis. J Clin Cell Immunol. 2016;7:402.
- Lee SM, Dunnavant FD, Jang H, et al. Autoantibodies that recognize functional domains of hnRNPA1 implicate molecular mimicry in the pathogenesis of neurological disease. Neurosci Lett. 2006;401:188–193.
- Bednenko J, Cingolani G, Gerace L. Importin β contains a COOH-terminal nucleoporin binding region important for nuclear transport. J Cell Biol. 2003;162:391.
- Levin MC, Lee S, Gardner LA, et al. Pathogenic mechanisms of neurodegeneration based on the phenotypic expression of progressive forms of the immune-mediated neurologic disease. Dove Press. 2012;5:175–187.
- Kim HJ, Kim NC, Wang Y-D, et al. Prion-like domain mutations in hnRNPs cause multisystem proteinopathy and ALS. Nature. 2013;495:467–473.
- Liu Q, Shu RR, Wang LA, et al. Whole-exome sequencing identifies a missense mutation in hnRNPA1 in a family with flail arm ALS. Neurology. 2016;87:1763–1769.
- Lee YH, Seo YH, Kim JH, Choi SJ, Ji JD, Song GG. Meta-analysis of associations between MTHFR and GSTIN polymorphism and susceptibility to multiple sclerosis. Neurosci Lett. 2015;36(11):2089–2096.